Blog Post Title: Stock Update – August 15, 2023
Introduction: OKYO Pharma Limited Announces Positive Developments with Flagship Drug OK-101 to Treat Dry Eye Disease OKYO Pharma Limited (NASDAQ: OKYO), a leading ophthalmology-focused bio-pharmaceutical company, has reported financial results for the twelve months ended March 31, 2023, along with an update on its lead program, OK-101. The company’s CEO, Gary Jacob, expressed his satisfaction…